Upregulation of glucosamine-phosphate N-acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma

• Published in: Oncology letters 2021-06, Vol.21 (6), p.488-488, Article 488
• Main Authors: Zhu, Pengyuan, Gu, Shaorui, Huang, Haitao, Zhong, Chongjun, Liu, Zhenchuan, Zhang, Xin, Wang, Wenli, Xie, Shiliang, Wu, Kaiqin, Lu, Tiancheng, Zhou, Yongxin
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Analysis; Biomarkers; Cancer; Cell cycle; Classification; Cyclin-dependent kinases; Development and progression; Diagnosis; DNA binding proteins; DNA methylation; Epigenetics; Folic acid; Gene expression; Genes; Genetic aspects; Genomes; Genotype & phenotype; Hormones, Sex; Kinases; Lung cancer; Lung cancer, Non-small cell; Medical diagnosis; Medical prognosis; Metabolism; Metastasis; Mutation; Oncology; Oncology, Experimental; Patient outcomes; Patients; Phosphates; Polyclonal antibodies; Proteins; Proteolysis; Survival analysis; Tumors; Type 2 diabetes
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2021.12750

Lung adenocarcinoma, a type of non-small cell lung cancer, is the leading cause of cancer death worldwide. Great efforts have been made to identify the underlying mechanism of adenocarcinoma, especially in relation to oncogenes. The present study by integrating computational analysis with western blotting, aimed to understand the role of the upregulation of glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1) in carcinogenesis. In the present study, publicly available gene expression profiles and clinical data were downloaded from The Cancer Genome Atlas to determine the role of GNPNAT1 in lung adenocarcinoma (LUAD). In addition, the association between LUAD susceptibility and GNPNAT1 upregulation were analyzed using Wilcoxon signed-rank test and logistic regression analysis. In LUAD, GNPNAT1 upregulation was significantly associated with disease stage [odds ratio (OR)=2.92, stage III vs. stage I], vital status (dead vs. alive, OR=1.89), cancer status (tumor status vs. tumor-free status, OR=1.85) and N classification (yes vs. no, OR=1.75). Cox regression analysis and the Kaplan-Meier method were utilized to evaluate the association between GNPNAT1 expression and overall survival (OS) time in patients with LUAD. The results demonstrated that patients with increased GNPNAT1 expression levels exhibited a reduced survival rate compared with those with decreased expression levels (P=8.9×10 ). In addition, Cox regression analysis revealed that GNPNAT1 upregulation was significantly associated with poor OS time [hazard ratio (HR): 1.07; 95% confidence interval (CI): 1.04-1.10; P